Skip to search formSkip to main contentSkip to account menu

MN 001

Known as: MN-001, MN001 cpd 
National Institutes of Health

Related topics

Related topics

2 relations
KCA 757

Broader (1)

Tipelukast

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The anti-fibrotic agent, tipelukast (MN-001) reduces serum triglyceride significantly in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease patients with hypertriglyceridemia after 4…
2016
2016
Burkholderia contaminans Biofilm Regulating Operon and Its Distribution in Bacterial Genomes
Biofilm formation by Burkholderia spp. is a principal cause of lung chronic infections in cystic fibrosis patients. A “lacking… 
2014
2014
MN-001 (tipelukast), a nonselective phosphodiesterase, 5-lipoxygenase, leukotriene, phospholipase C and thromboxane A2 inhibitor, demonstrates anti-fibrotic effects in the Bleomycin-induced…
2007
2007
MN 001: KCA 757, KCA-757, MN-001.
MN 001 is an orally bioavailable anti-inflammatory agent, originated by Kyorin Pharmaceutical, which is being developed in… 
2007
2007
Effects Of MN-001 In Patients With Mild-to-moderate Asthma In A Randomized, Double-blind And Placebo-controlled Phase II Study
2006
2006
MN‐001, a novel oral anti‐inflammatory agent, suppresses bladder hyperactivity in a rat model
To evaluate the effects of MN‐001, a novel orally active anti‐inflammatory agent, in suppressing the bladder hyperactivity… 
2005
2005
Phase I study of MN-001, an oral anti-inflammatory agent for the treatment of asthma
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)